Key result
Non-cutaneous de novo malignancies develop in ~7% of heart transplant recipients, driven by lung neoplasms.
Why the study?
Malignancies are a recognized complication of long-term immunosuppressive therapy after cardiac transplantation, but the incidence and spectrum of non-cutaneous de novo malignant neoplasms require investigation.
Population
267 patients surviving more than 1 month after cardiac transplantation
Design
Cohort study
Follow-up
Mean interval 36 months from transplantation to tumor diagnosis
Authors
Loading...
May warrant heightened lung cancer vigilance in smokers post-transplant; leaves open prospective validation of screening strategies.
Cohort (n=267)
No
Following cardiac transplantation, there is a notable incidence of de novo lung neoplasms, which appears to correlate with heavy cigarette use in the recipient population.
Curtil et al. (1997) conducted a cohort in Cardiac transplantation (n=267). Cardiac transplantation and immunosuppressive therapy was evaluated on Development of non-cutaneous de novo malignant neoplasms. Following cardiac transplantation, non-cutaneous de novo malignant neoplasms developed in 6.7% of patients, with a notably high incidence of lung neoplasms (4.1%) correlated with heavy smoking.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: